Member Info for Yorkshirepragma

Https://www.daiichisankyo.com/files/investors/library/materials/2023/March%202024%20ENHERTU%20Business%20Briefing_E_Final.pdf

It’s all joined up …

“here is essentially in order to get a drug through the FDA you are talking to the experts and convincing them but yet it is safe. Yes it has has a chance for doing something doing some good for the patients and that we were saying they’ve seen what we presented with them them and they really excited about it. I wanted to get forward so that’s why we think it’s been the risk because the experts have looked at it and said this is a good thing “

It’s on plc site under academy. Regards

Francis ‘ comments on FDA at end of session most telling ..

In addition to the inestimable ethical value..

pancreatic

~USD 3.82 billion in 2025 and projected to reach over USD 14 billion by 2034

Cervical

~USD 930 million in 2023 Rising due to HIV

Gastric

~USD 7 billion in 2025 and projected to exceed USD 12–31 billion by 2030-2034,

Small cell lung

~ projected to reach between $5.1 billion and $13.95 billion by 2030-2032

Https://www.linkedin.com/posts/avacta_oncology-clinicaltrials-cancerresearch-activity-7420080214677827584-NMZL?utm_source=share&utm_medium=member_ios&rcm=ACoAAAPkCiYBHtTJNIz1eN2Rcmr0FlqMoKwJop0

Several oncology companies, including Daiichi Sankyo and AstraZeneca, have developed or licensed antibody-drug conjugates based on exatecan derivatives. These ADCs use monoclonal antibodies to target cell surface antigens like HER2 or TROP2, delivering the payload upon internalization. While clinically effective, these ADCs face challenges including low antigen expression in some tumors, limited penetration in large or fibrotic tumors, and off-target effects in normal tissues that express the same antigens at lower levels.

AVA6103 takes a different route. It bypasses surface receptor targeting and instead leverages a tumor-expressed enzyme to trigger release of its payload. This extracellular cleavage strategy, enabled by a proprietary peptide linker that is selectively cleaved by FAP, offers two theoretical advantages: deeper tissue penetration due to the small size of the PDC and reduced off-target toxicity due to limited systemic exposure. Whether these benefits can be realized in humans remains to be seen, but the approach carves out a distinct niche in the exatecan development landscape.

CC refers to other applications …Chronic Inflammation ‘conversations’ are interesting . One step at a time ….

Fascinating similarity re Avactas current development processes.

Tuesday 24th February 2026

The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies

9:15 am

Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit

Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design

Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates

Https://x.com/MylesMcNulty/status/2014367132532838749?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

Https://www.biopharmadive.com/news/johnson-johnson-halda-acquire-cancer-drugs-riptac/805662/

Commercial focus in recent RNS’s gives strong message.

Not often these ‘signals’ given .

GLA

Declared Global pharma interests….that’ll do

Important to note that this is my invitation only.

Novartis 2/1

AZ 4/5

Indupro at pre clinical …illustrates interest in early tech is becoming norm.

Https://www.grandviewresearch.com/industry-analysis/doxorubicin-market

https://www.databridgemarketresearch.com/reports/global-soft-tissue-sarcomas-treatment-market

https://www.verifiedmarketreports.com/product/salivary-gland-cancer-treatment-market/

Https://haldatx.com/halda-therapeutics-announces-first-in-human-results-for-hld-0915-an-oral-riptac-therapeutic-demonstrating-encouraging-safety-and-anti-tumor-activity-in-metastatic-castration-resistance-prost/

Basis … lower antigen results . Not in phase 2

Https://www.biopharmadive.com/news/johnson-johnson-halda-acquire-cancer-drugs-riptac/805662/